Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, Opt-in with us: www.register.msviewsandnews.org

Please visit our MS learning channel on YouTube, which provides hundreds of MS topics presented by MS Experts across the USA, from many of our video recorded education programs. Archived here: www.youtube.com/msviewsandnews -- PLUS Visit our Social media platforms: Facebook, Twitter, and Instagram

~~ Left side of this blog shows resources, needed by many. Easiest way to find topic or articles is to use our 'search by topic' tool, to find specific information ~~

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Monday, March 30, 2009

Fampridine-SR (4-aminopyridine) is a new drug in development to help improve walking ability in people with multiple sclerosis

Fampridine-SR ("4-aminopyridine", "4-AP", “fampridine”) is an investigational oral, sustained-release tablet formulation of 4-aminopyridine. In laboratory studies fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged.


Clinical History of Fampridine-SR in Multiple Sclerosis (MS)

Acorda recently completed a Phase 3 clinical study of Fampridine-SR to evaluate its safety and efficacy in improving walking ability in people with all types of MS.

View a video* illustrating Fampridine-SR’s mechanism of action:

Large (4.0MB)
Small (2.8MB)

Researchers have shown that, contrary to popular belief, most people with spinal cord injury (SCI) do not have severed cords; rather, most have blunt damage to the cord. The great majority of such individuals have some axons within the spinal cord that survive the injury. However, these surviving axons often are damaged and lose part of their myelin, the insulating sheath that permits electrical impulses to be conducted down the axon. Nerve impulses "short circuit" in demyelinated axons, much like electricity in a wire whose insulation is stripped. Thus, even though a demyelinated axon is alive, it cannot transmit motor or sensory impulses. In multiple sclerosis (MS), the myelin is believed to be damaged by the body's own immune system, rather than by physical trauma as in SCI.

Fampridine-SR's major action is to block specialized potassium channels on axons. When an axon is demyelinated after injury, large numbers of these potassium channels are exposed and "leak" potassium ions, causing the axon to "short circuit".

By closing the exposed potassium channels, Fampridine-SR permits the axon to transmit impulses again, even in a demyelinated state.

*Video requires Quicktime to view. Download Quicktime now.


Tell us what you think of this hopeful new medication. Thank You
============================================

1 comment:

Anonymous said...

I have been following this drug for about 2 years now and hope it will help. I have been helped somewhat with Tysabri but hope this drug will help w/ walking longer and further. I miss really taking a walk and it is my hope Fampridine will fulfill this dream. I can survive most of these lousy symptoms, but I really miss the feeling and joy of walking ..anywhere I want. Let's keep our fingers and toes crossed!!